{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ganapathy B"],"funding":["NCRR NIH HHS","Fondation Leducq","National Heart, Lung, and Blood Institute","NHLBI NIH HHS"],"pagination":["e0155456"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4866786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(5)"],"pubmed_abstract":["Background
We previously developed and validated a strategy for stimulating heart regeneration by administration of recombinant neuregulin (rNRG1), a growth factor, in mice. rNRG1 stimulated proliferation of heart muscle cells, cardiomyocytes, and was most effective when administration began during the neonatal period. Our results suggested the use of rNRG1 to treat pediatric patients with heart failure. However, administration in this age group may stimulate growth outside of the heart.Methods
NRG1 and ErbB receptor expression was determined by RT-PCR. rNRG1 concentrations in serum were quantified by ELISA. Mice that received protocols of recombinant neuregulin1-β1 administration (rNRG1, 100 ng/g body weight, daily subcutaneous injection for the first month of life), previ"],"journal":["PloS one"],"pubmed_title":["Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth."],"pmcid":["PMC4866786"],"funding_grant_id":["R01 HL106302","K08 HL085143","K08HL085143","15CVD03","R01HL106302","S10 RR028792","T32HL007572","T32 HL007572"],"pubmed_authors":["Polizzotti BD","Bennett D","Ganapathy B","Nandhagopal N","Asan A","Wu Y","Kuhn B"],"additional_accession":[]},"is_claimable":false,"name":"Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth.","description":"Background
We previously developed and validated a strategy for stimulating heart regeneration by administration of recombinant neuregulin (rNRG1), a growth factor, in mice. rNRG1 stimulated proliferation of heart muscle cells, cardiomyocytes, and was most effective when administration began during the neonatal period. Our results suggested the use of rNRG1 to treat pediatric patients with heart failure. However, administration in this age group may stimulate growth outside of the heart.Methods
NRG1 and ErbB receptor expression was determined by RT-PCR. rNRG1 concentrations in serum were quantified by ELISA. Mice that received protocols of recombinant neuregulin1-β1 administration (rNRG1, 100 ng/g body weight, daily subcutaneous injection for the first month of life), previ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2025-04-04T11:14:43.577Z","creation":"2019-03-26T22:54:55Z"},"accession":"S-EPMC4866786","cross_references":{"pubmed":["27175488"],"doi":["10.1371/journal.pone.0155456"]}}